TY - JOUR T1 - Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. AU - Link-Gelles,Ruth, AU - Levy,Matthew E, AU - Gaglani,Manjusha, AU - Irving,Stephanie A, AU - Stockwell,Melissa, AU - Dascomb,Kristin, AU - DeSilva,Malini B, AU - Reese,Sarah E, AU - Liao,I-Chia, AU - Ong,Toan C, AU - Grannis,Shaun J, AU - McEvoy,Charlene, AU - Patel,Palak, AU - Klein,Nicola P, AU - Hartmann,Emily, AU - Stenehjem,Edward, AU - Natarajan,Karthik, AU - Naleway,Allison L, AU - Murthy,Kempapura, AU - Rao,Suchitra, AU - Dixon,Brian E, AU - Kharbanda,Anupam B, AU - Akinseye,Akintunde, AU - Dickerson,Monica, AU - Lewis,Ned, AU - Grisel,Nancy, AU - Han,Jungmi, AU - Barron,Michelle A, AU - Fadel,William F, AU - Dunne,Margaret M, AU - Goddard,Kristin, AU - Arndorfer,Julie, AU - Konatham,Deepika, AU - Valvi,Nimish R, AU - Currey,J C, AU - Fireman,Bruce, AU - Raiyani,Chandni, AU - Zerbo,Ousseny, AU - Sloan-Aagard,Chantel, AU - Ball,Sarah W, AU - Thompson,Mark G, AU - Tenforde,Mark W, Y1 - 2022/07/22/ PY - 2022/7/21/entrez PY - 2022/7/22/pubmed PY - 2022/7/26/medline SP - 931 EP - 939 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 71 IS - 29 N2 - The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in the United States in November 2021, with the BA.1 sublineage (including BA.1.1) causing the largest surge in COVID-19 cases to date. Omicron sublineages BA.2 and BA.2.12.1 emerged later and by late April 2022, accounted for most cases.* Estimates of COVID-19 vaccine effectiveness (VE) can be reduced by newly emerging variants or sublineages that evade vaccine-induced immunity (1), protection from previous SARS-CoV-2 infection in unvaccinated persons (2), or increasing time since vaccination (3). Real-world data comparing VE during the periods when the BA.1 and BA.2/BA.2.12.1 predominated (BA.1 period and BA.2/BA.2.12.1 period, respectively) are limited. The VISION network† examined 214,487 emergency department/urgent care (ED/UC) visits and 58,782 hospitalizations with a COVID-19-like illness§ diagnosis among 10 states during December 18, 2021-June 10, 2022, to evaluate VE of 2, 3, and 4 doses of mRNA COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) compared with no vaccination among adults without immunocompromising conditions. VE against COVID-19-associated hospitalization 7-119 days and ≥120 days after receipt of dose 3 was 92% (95% CI = 91%-93%) and 85% (95% CI = 81%-89%), respectively, during the BA.1 period, compared with 69% (95% CI = 58%-76%) and 52% (95% CI = 44%-59%), respectively, during the BA.2/BA.2.12.1 period. Patterns were similar for ED/UC encounters. Among adults aged ≥50 years, VE against COVID-19-associated hospitalization ≥120 days after receipt of dose 3 was 55% (95% CI = 46%-62%) and ≥7 days (median = 27 days) after a fourth dose was 80% (95% CI = 71%-85%) during BA.2/BA.2.12.1 predominance. Immunocompetent persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19, including a first booster dose for all eligible persons and second booster dose for adults aged ≥50 years at least 4 months after an initial booster dose. Booster doses should be obtained immediately when persons become eligible.¶. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/35862287/Effectiveness_of_2_3_and_4_COVID_19_mRNA_Vaccine_Doses_Among_Immunocompetent_Adults_During_Periods_when_SARS_CoV_2_Omicron_BA_1_and_BA_2/BA_2_12_1_Sublineages_Predominated___VISION_Network_10_States_December_2021_June_2022_ DB - PRIME DP - Unbound Medicine ER -